GlassScriptPhysician profile
Ashley Ann Ceithaml
NPI 1881351120
$1,345.86
in general payments reported to CMS, 2019-2025
25 companies · $679 in 2025
The $679 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.86 · 2023: $171 · 2024: $478 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $251.70 | 2024-2025 | |
| Astellas Pharma US INC | $211.84 | 2024-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $112.71 | 2024-2025 | |
| Sage Therapeutics, LLC | $98.93 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $98.31 | 2024-2025 | Myfembree |
| Abbvie INC. | $80.09 | 2024-2025 | |
| Pfizer INC. | $74.32 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $40.68 | 2022-2023 | Ztlido |
| Vertical Pharmaceuticals, LLC | $38.20 | 2024 | Dsuvia |
| Shield Therapeutics INC | $35.20 | 2023-2024 | Accrufer |
| Team 1, LLC | $33.33 | 2025 | |
| Dexcom, INC. | $31.22 | 2025 | Dexcom G6 Transmitter |
| Millicent US INC | $29.90 | 2025 | Femlyv, Intrarosa |
| Protega Pharmaceutials INC | $24.27 | 2023 | Roxybond |
| Coopersurgical, INC. | $23.14 | 2025 | Paragard T 380a |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lsi Solutions INC | $20.66 | 2024 | Fornisee |
| Agile Therapeutics, INC. | $19.11 | 2024 | Twirla |
| Orexo US, INC. | $17.87 | 2023 | Zubsolv |
| Amneal Pharmaceuticals LLC | $16.82 | 2023 | Lyvispah |
| Olympus America INC. | $16.47 | 2024 | Olympus |
| Exact Sciences Corporation | $14.77 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $14.45 | 2023 | Zepbound |
| Vivus LLC | $14.29 | 2024 | Qsymia |
| Exeltis, USA INC. | $13.94 | 2025 | Slynd |
| Innovation Technologies INC | $13.64 | 2025 | Irrisept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Ceithaml listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.